TY - JOUR
T1 - When a Uniquely Effective Drug is Teratogenic
T2 - The Case of Isotretinoin
AU - Holmes, Andrew
AU - Wolfe, Sidney
AU - Faich, Gerald
AU - Rosa, Franz
AU - Stern, Robert S.
AU - Mitchell, Allen A.
PY - 1989/9/14
Y1 - 1989/9/14
N2 - To the Editor: Just one week after a Journal editorial on the disclosure of investigators' financial ties (April 6 issue),1 there was a Sounding Board article on isotretinoin (Accutane) by Dr. Robert Stern (April 13 issue),2 in which no disclosure was made of his substantial association with Hoffmann–LaRoche (Roche), the manufacturer of isotretinoin. At the April 26, 1988, meeting of the Dermatologic Drugs Advisory Committee of the Food and Drug Administration, Dr. Stern disqualified himself from voting on Accutane because of what he described as “my continuing support for a research project from Hoffmann–LaRoche company and other consulting work I…
AB - To the Editor: Just one week after a Journal editorial on the disclosure of investigators' financial ties (April 6 issue),1 there was a Sounding Board article on isotretinoin (Accutane) by Dr. Robert Stern (April 13 issue),2 in which no disclosure was made of his substantial association with Hoffmann–LaRoche (Roche), the manufacturer of isotretinoin. At the April 26, 1988, meeting of the Dermatologic Drugs Advisory Committee of the Food and Drug Administration, Dr. Stern disqualified himself from voting on Accutane because of what he described as “my continuing support for a research project from Hoffmann–LaRoche company and other consulting work I…
UR - http://www.scopus.com/inward/record.url?scp=85013874041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013874041&partnerID=8YFLogxK
U2 - 10.1056/NEJM198909143211110
DO - 10.1056/NEJM198909143211110
M3 - Letter
AN - SCOPUS:85013874041
SN - 0028-4793
VL - 321
SP - 756
EP - 758
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 11
ER -